Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc.

“For families facing brain cancer, access to investigational treatments and clinical research opportunities matters deeply. This proposed collaboration creates a framework to bring NeOnc’s development expertise together with Abu Dhabi’s clinical capabilities, with the goal of advancing research and expanding opportunities for patients closer to home. We are grateful to the Department of Health – Abu Dhabi for its commitment to addressing the needs of patients with complex and rare CNS cancers, including children.”

Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi

“For patients and families facing complex CNS cancers, every advance in research offers hope for more effective care and better quality of life. Our proposed collaboration with NeOnc connects international expertise with Abu Dhabi’s clinical capabilities to strengthen the evidence and skills needed to evaluate new approaches responsibly. By developing specialist knowledge and a deeper understanding of these critical conditions, we aim to support care that responds more closely to each patient’s needs, reflecting our commitment to bringing scientific advances closer to our community and beyond.”

Eiry W. Roberts, Chief Medical Officer, Neurocrine Biosciences

“As a defining characteristic of Alzheimer’s disease, cognitive impairment affects memory, attention, and other thinking abilities that significantly impact daily functioning,”

Eiry W. Roberts, Chief Medical Officer, Neurocrine Biosciences

“The advancement of NBI-’567 reflects our commitment to delivering new treatment options for this vulnerable population, in addition to our broader strategy to explore the potential of selectively targeting muscarinic receptors across a range of neurological and psychiatric conditions.”

Terrie Kellmeyer, Interim Chief Executive Officer, Anavex Life Sciences Corp.

“FDA clearance of the Fragile X IND is an important milestone that gives Anavex open INDs in all three of our core indications: Alzheimer’s Disease, Rett syndrome, and Fragile X syndrome, and supports our continued momentum of working closely with the FDA as we move our programs forward.”

Terrie Kellmeyer, Interim Chief Executive Officer, Anavex Life Sciences Corp.

“With an open IND, we are positioned to advance ANAVEX2-73-FXS-001, a planned Phase 2a randomized, double-blind, placebo-controlled, dose-ranging study of the safety, tolerability, and pharmacokinetics of blarcamesine oral solution in approximately 60 adult males with FXS, with behavioral (Aberrant Behavior Checklist revised for FXS “ABCFX”) and cognitive (NIH Toolbox) measures included as secondary endpoints.”

Terrie Kellmeyer, Interim Chief Executive Officer, Anavex Life Sciences Corp.

“We believe blarcamesine’s differentiated mechanism of action, including its targeting of sigma-1 receptors, uniquely positions Anavex with the potential to pioneer a transformative treatment approach for patients and families affected by Fragile X syndrome.”

Marjorie Green, Senior vice president and head of oncology global clinical development, Merck Research Laboratories

“New data at ESMO, including three Presidential Symposia from three pivotal trials, reflect the strength and depth of Merck’s industry-leading oncology portfolio and pipeline. We are proud to share Phase 3 data for the first time from intismeran and sac-TMT, alongside new research from our oncology portfolio, reflecting our commitment to advancing research across a range of cancer types.”